AI MARKET SCANNING

AbCellera Biologics Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -3.90%
MAX GAP RECORD -16.11%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ABCL
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
-2.20%
May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE)
-9.33%
Feb 24, 2026 Earnings Release 2026-02-24 (AFTER CLOSE)
+4.35%
Nov 06, 2025 Earnings Release 2025-11-06 (AFTER CLOSE)
-16.11%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
+13.68%
May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE)
+1.99%
Feb 27, 2025 Earnings Release 2025-02-27 (AFTER CLOSE)
-6.85%
Nov 04, 2024 Earnings Release 2024-11-04 (AFTER CLOSE)
-13.49%

VOLATILITY & GAP BIAS

AVG GAP MOVE 6.8%
Bullish Gaps (3)
Bearish Gaps (11)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ABCL

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗